SwePub
Sök i LIBRIS databas

  Extended search

WFRF:(Lytken Larsen Mogens)
 

Search: WFRF:(Lytken Larsen Mogens) > (2009) > Total Cardiovascula...

  • Tikkanen, Matti JUniv Helsinki, Cent Hosp, Dept Med, Div Cardiol, FIN-00290 Helsinki, Finland (author)

Total Cardiovascular Disease Burden: Comparing Intensive With Moderate Statin Therapy Insights From the IDEAL (Incremental Decrease in End Points Through Aggressive Lipid Lowering) Trial

  • Article/chapterEnglish2009

Publisher, publication year, extent ...

  • Elsevier BV,2009
  • printrdacarrier

Numbers

  • LIBRIS-ID:oai:DiVA.org:liu-52890
  • https://urn.kb.se/resolve?urn=urn:nbn:se:liu:diva-52890URI
  • https://doi.org/10.1016/j.jacc.2009.08.035DOI

Supplementary language notes

  • Language:English
  • Summary in:English

Part of subdatabase

Classification

  • Subject category:ref swepub-contenttype
  • Subject category:art swepub-publicationtype

Notes

  • Objectives This post-hoc analysis of the IDEAL (Incremental Decrease in End Points Through Aggressive Lipid Lowering) trial was designed to assess the comparative treatment efficacy of high-dose atorvastatin and usual-dose simvastatin for the prevention of events subsequent to the first event, using the Wei, Lin, and Weissfeld method. Background Time-to-first-event analysis of data is frequently utilized to provide efficacy outcome information in coronary heart disease prevention trials. However, during the course of such long-term trials, a large number of events occur subsequent to the first event, the analysis of which will be precluded by this approach. Methods The Wei, Lin, and Weissfeld method allows the analysis of repeated occurrence of events of the same type or of entirely different natures. It regards the recurrence times as multivariate event (failure) times, and models the marginal (individual) distribution for each event with the Cox proportional hazards model. Results In the IDEAL trial, compared with patients taking simvastatin 20 to 40 mg daily, patients receiving atorvastatin 80 mg daily had their relative risk of a first cardiovascular event reduced by 17% (p less than 0.0001), of a second by 24% (p less than 0.0001), of a third by 19% (p = 0.035), of a fourth by 24% (p = 0.058), and of a fifth by 28% (p = 0.117). Conclusions Our results indicate that intensive statin therapy continues to be more effective than standard statin therapy, even beyond the first event, and suggest that clinicians should not hesitate to prescribe high-dose statin therapy for patients experiencing multiple recurrent cardiovascular events.

Subject headings and genre

  • statins; cardiovascular events; WLW method
  • MEDICINE
  • MEDICIN

Added entries (persons, corporate bodies, meetings, titles ...)

  • Szarek, MichaelPfizer Inc, New York, NY USA (author)
  • Fayyad, RanaPfizer Inc, New York, NY USA (author)
  • Holme, IngarUllevaal Univ Hosp, Ctr Prevent Med, Oslo, Norway (author)
  • Cater, Nilo BPfizer Inc, New York, NY USA (author)
  • Faergeman, OleAarhus Univ Hosp, Dept Med Cardiol A, DK-8000 Aarhus, Denmark (author)
  • Kastelein, John J PAcad Hosp Amsterdam, Dept Vasc Med, Amsterdam, Netherlands (author)
  • Olsson, AndersÖstergötlands Läns Landsting,Linköpings universitet,Internmedicin,Hälsouniversitetet,Endokrin- och magtarmmedicinska kliniken US(Swepub:liu)andol21 (author)
  • Lytken Larsen, MogensDepartment of Medicine-Cardiology A, Århus University Hospital, Århus, Denmark (author)
  • Lindahl, ChristinaPfizer Sweden, Sollentuna, Sweden (author)
  • Pedersen, Terje RUllevaal Univ Hosp, Ctr Prevent Med, Oslo, Norway (author)
  • Univ Helsinki, Cent Hosp, Dept Med, Div Cardiol, FIN-00290 Helsinki, FinlandPfizer Inc, New York, NY USA (creator_code:org_t)

Related titles

  • In:Journal of the American College of Cardiology: Elsevier BV54:25, s. 2353-23570735-10971558-3597

Internet link

Find in a library

To the university's database

Kungliga biblioteket hanterar dina personuppgifter i enlighet med EU:s dataskyddsförordning (2018), GDPR. Läs mer om hur det funkar här.
Så här hanterar KB dina uppgifter vid användning av denna tjänst.

 
pil uppåt Close

Copy and save the link in order to return to this view